Lymphocyte Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Lymphocyte clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 2

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Nodular Lymphocyte Predominant B-Cell LymphomaRecurrent Nodular Lymphocyte Predominant B-Cell LymphomaRefractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)70 enrolled35 locationsNCT05886036
Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Nodular Lymphocyte-Predominant Hodgkin Lymphoma
St. Jude Children's Research Hospital100 enrolled7 locationsNCT06098430
Recruiting

INS, B Cells and Microbiota

MicrobiotaB-lymphocytesGlomerulosclerosis+1 more
Nantes University Hospital30 enrolled2 locationsNCT04924712
Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Early Phase 1

A Study of GC203 TIL in PDCA (RJ)

Pancreatic CancerTreatment Side EffectsTumor Infiltrating Lymphocytes+1 more
Shanghai Juncell Therapeutics10 enrolled1 locationNCT06828328
Recruiting
Early Phase 1

A Study of TIL in Advanced Solid Tumors (DFGD)

Advanced Solid TumorTreatment Side EffectsEffects of Immunotherapy+1 more
Shanghai Juncell Therapeutics30 enrolled1 locationNCT06488950
Recruiting
Early Phase 1

A Study of GC101 TIL in Advanced Melanoma (10hospital)

Advanced MelanomaTreatment Side EffectsEffects of Immunotherapy+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05098184
Recruiting
Early Phase 1

A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

Treatment Side EffectsEffects of ImmunotherapyTumor Infiltrating Lymphocyte+2 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05098197
Recruiting
Phase 1

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

T-cell Prolymphocytic LeukemiaT-cell LymphomasNK-Cell Lymphomas+1 more
Memorial Sloan Kettering Cancer Center70 enrolled9 locationsNCT05010005
Recruiting
Phase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658
Recruiting

Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.

Intensive Care UnitPlateletsNeutrophils to Lymphocytes+4 more
Ain Shams University290 enrolled1 locationNCT07200817
Recruiting

Neutrophil to Lymphocyte Ratio and Postdural Headache

Preoperative Neutrophil-to-Lymphocyte Ratio (NLR)
Istinye University821 enrolled1 locationNCT07075874
Recruiting
Phase 1

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Lymphocytes
H. Lee Moffitt Cancer Center and Research Institute30 enrolled1 locationNCT06047977
Recruiting
Phase 1

Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer (CRC)PD-1Tumor Infiltrating Lymphocytes
Ruijin Hospital29 enrolled1 locationNCT07035002
Recruiting

Is the CRP-Albumin-Lymphocyte (CALLY) Index Effective in Predicting Postoperative Delirium in Geriatric Patients Undergoing Hip Fracture Surgery

Postoperative Delirium (POD)Hip FractureCRP+2 more
Ankara Ataturk Sanatorium Training and Research Hospital100 enrolled1 locationNCT06818409
Recruiting

Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer

Pancreatic Cancer, AdultPerineural InvasionNeutrophil-to-Lymphocyte Ratio+1 more
University of Las Palmas de Gran Canaria323 enrolled1 locationNCT06747481
Recruiting
Early Phase 1

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

LeukemiaHematopoetic Stem Cell TransplantationDonor Lymphocyte Infusion
University of Arizona100 enrolled1 locationNCT06643221
Recruiting
Early Phase 1

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

Advanced Solid TumorTreatment Side EffectsEffects of Immunotherapy+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05087745
Recruiting
Phase 2

Nutritional polypill trial in well subjects in order to assess genome damage

Damage in lymphocyte deoxyribonucleic acid (DNA)
NHMRC250 enrolled1 locationACTRN12607000651482